NCT01412710

Brief Summary

The purpose of the present pilot study is to determine the effect of vitamin D supplementation (4000 IU or 6000 IU once daily for 6 months) on reducing heart disease risk and in improving blood glucose control in type 2 Diabetes subjects . The investigators are working with Hispanics and African Americans living in Miami, Florida.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
92

participants targeted

Target at P50-P75 for not_applicable type-2-diabetes

Timeline
Completed

Started Jul 2011

Typical duration for not_applicable type-2-diabetes

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2011

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

August 7, 2011

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 9, 2011

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2013

Completed
4.3 years until next milestone

Results Posted

Study results publicly available

December 12, 2017

Completed
Last Updated

December 12, 2017

Status Verified

October 1, 2017

Enrollment Period

2.2 years

First QC Date

August 7, 2011

Results QC Date

August 5, 2017

Last Update Submit

November 13, 2017

Conditions

Keywords

Type 2 DiabetesCholecalciferolVitamin DInsulin resistanceCardiovascular disease riskMinorities

Outcome Measures

Primary Outcomes (1)

  • Blood Lipid

    Total cholesterol will be used as surrogate measures for cardiovascular disease risk.

    Baseline

Secondary Outcomes (1)

  • Glycemic Control

    Baseline

Study Arms (2)

4000 IU group

EXPERIMENTAL

This group will be given 4000 IU of vitamin D3 once daily, orally for 6 months.

Drug: Cholecalciferol

6000 IU group

EXPERIMENTAL

This group will be given 6000 IU vitamin D3 once daily, orally for 6 months.

Drug: Cholecalciferol

Interventions

4000 IU or 6000 IU given vitamin D3 once daily, orally for 6 months.

Also known as: Vitamin D
4000 IU group6000 IU group

Eligibility Criteria

Age30 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Type 2 diabetes
  • African American or Hispanic
  • able to ambulate on their own
  • aged between 30 - 70 years

You may not qualify if:

  • Taking Supplemental Vitamin D
  • Pregnant or Lactating women
  • Receiving insulin therapy
  • Not participating in other drug trials
  • HIV/ hepatitis/ cancer/ liver disease/ heart failure/ any recent surgery/ mental illness/ epilepsy/ any GI or malabsorption disorders
  • Kidney failure or on dialysis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Human Nutrition Laboratory, Florida International University

Miami, Florida, 33199, United States

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2Insulin Resistance

Interventions

CholecalciferolVitamin D

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesHyperinsulinism

Intervention Hierarchy (Ancestors)

CholestenesCholestanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSterolsSecosteroidsMembrane LipidsLipids

Limitations and Caveats

The study sample was a convenience sample and was not randomly selected from the general adult population. The study lacked a control group.

Results Point of Contact

Title
Fatma G. Huffman
Organization
Florida International University

Study Officials

  • Fatma G Huffman, PhD

    Florida International University

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr. Fatma G. Huffman

Study Record Dates

First Submitted

August 7, 2011

First Posted

August 9, 2011

Study Start

July 1, 2011

Primary Completion

September 1, 2013

Study Completion

September 1, 2013

Last Updated

December 12, 2017

Results First Posted

December 12, 2017

Record last verified: 2017-10

Locations